RSS-Feed abonnieren
DOI: 10.1055/a-1796-2471
Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss screening study – outcomes, adherence, and costs
Langzeitüberwachung nach dem kolorektalen Karzinomscreening mittels Koloskopie in einer prospektiven Bevölkerungsstudie in der Schweiz: Resultate, Adhärenz und KostenAbstract
Background The success of colorectal cancer (CRC) screening depends mainly on screening quality, patient adherence to surveillance, and costs. Consequently, it is essential to assess the performance over time.
Methods In 2000, a closed cohort study on CRC screening in individuals aged 50 to 80 was initiated in Uri, Switzerland. Participants who chose to undergo colonoscopy were followed over 18 years. We investigated the adherence to recommended surveillance and collected baseline characteristics and colonoscopy data. Risk factors at screening for the development of advanced adenomas were analyzed. Costs for screening and follow-up were evaluated retrospectively.
Results 1278 subjects with a screening colonoscopy were included, of which 272 (21.3%; 69.5% men) had adenomas, and 83 (6.5%) had advanced adenomas. Only 59.8% participated in a follow-up colonoscopy, half of them within the recommended time interval. Individuals with advanced adenomas at screening had nearly five times the risk of developing advanced adenomas compared to individuals without adenomas (24.3% vs. 5.0%, OR 4.79 CI 2.30–9.95). Individuals without adenomas developed advanced adenomas in 4.9%, including four cases of CRC; three of them without control colonoscopy. The villous component in adenomas smaller than 10 mm was not an independent risk factor. Costs for screening and follow-up added up to CHF 1’934’521 per 1’000 persons screened, almost half of them for follow-up examinations; 60% of these costs accounted for low-risk individuals.
Conclusion Our findings suggest that follow-up of screening colonoscopy should be reconsidered in Switzerland; in particular, long-term adherence is critical. Costs for follow-up could be substantially reduced by adopting less expensive long-term screening methods for low-risk individuals.
Zusammenfassung
Hintergrund Hauptfaktoren einer erfolgreichen Darmkrebs-Früherkennung sind Qualität der Früherkennung, Bereitschaft der Patienten zur Teilnahme an der Überwachung und die Kosten. Eine regelmässige Evaluation des Screening-Programms ist zentral.
Methoden Im Jahr 2000 wurde in Uri, Schweiz, eine geschlossene Kohortenstudie zur Darmkrebsvorsorge bei Personen im Alter von 50 bis 80 Jahren initiiert. Teilnehmer, die sich für eine Koloskopie entschieden, wurden über 18 Jahre beobachtet. Wir untersuchten die Einhaltung der empfohlenen Vorsorgeuntersuchungen und erfassten die Ausgangscharakteristika und Koloskopiedaten. Risikofaktoren beim Screening für die Entwicklung fortgeschrittener Adenome wurden analysiert. Die Kosten für das Screening und die Nachsorge wurden retrospektiv ausgewertet.
Ergebnisse 1278 Personen mit einer Screening-Koloskopie wurden eingeschlossen, von denen 272 (21,3 %; 69,5 % Männer) Adenome und 83 (6,5 %) fortgeschrittene Adenome aufwiesen. Nur 59,8 % nahmen an einer Folgekoloskopie teil und hiervon die Hälfte innerhalb des empfohlenen Zeitraums. Personen mit fortgeschrittenen Adenomen beim Screening hatten ein fast fünfmal höheres Risiko, erneut fortgeschrittene Adenome zu entwickeln, als Personen mit unauffälliger Screeningkoloskopie (24,3 % vs. 5,0 %, OR 4,79 CI 2,30–9,95). 4.9% aller Personen ohne Adenome in der Screening-Kolonoskopie entwickelten im Verlauf fortgeschrittene Adenome, darunter vier CRC Fälle. 3 von diesen 4 CRC Fälle kamen nicht zur Kontrollkoloskopie. Die Kosten für das Screening und die Nachuntersuchung beliefen sich auf CHF 1’934’521 pro 1000 untersuchte Personen, fast die Hälfte davon entfiel auf die Nachuntersuchung. 60 % dieser Kosten entfielen auf Personen mit niedrigem Risiko.
Schlussfolgerung Unsere Ergebnisse deuten darauf hin, dass die Nachsorge der Screening-Koloskopie in der Schweiz neu überdacht werden sollte, da die Adhärenz über längeren Zeitraum schlecht ist. Die Kosten für die Nachuntersuchungen könnten erheblich gesenkt werden, wenn bei Personen mit geringem Risiko weniger teure Langzeit-Screening-Methoden angewandt würden.
Schlüsselwörter
Adenom - Karzinom - Koloskopie - Kolorektales Adenom - Kolorektales Karzinom - Kolorektale Polypen - VorsorgeuntersuchungKeywords
Adenoma - Cancer - Colonoscopy - Colorectal adenoma - Colorectal carcinoma - Colorectal polyps - ScreeningPublikationsverlauf
Eingereicht: 07. November 2021
Angenommen nach Revision: 02. März 2022
Artikel online veröffentlicht:
11. Mai 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 de Moor JS. et al. Colorectal cancer screening in the United States: Trends from 2008 to 2015 and variation by health insurance coverage. Prev Med 2018; 112: 199-206 DOI: 10.1016/j.ypmed.2018.05.001. (PMID: 29729288)
- 2 Siegel RL. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. J Natl Cancer Inst 2017; DOI: 10.1093/jnci/djw322. (PMID: 28376186)
- 3 Marbet U. Aktueller Stand des Kolonkarzinomscreenings (Fokus auf Stuhltest) L’état actuel du dépistage du carcinome colorectal (en particulier sur le test fécal) Stato attuale dello screening del carcinoma del colon (focus sul test delle feci). Schweizer Gastroenterologie 2020; 2: 1
- 4 Ran T. et al. Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review. Clin Gastroenterol Hepatol 2019; 17: 1969-1981 DOI: 10.1016/j.cgh.2019.01.014. (PMID: 30659991)
- 5 Manser CN. et al. Colonoscopy screening markedly reduces the occurrence of colon carcinomas and carcinoma-related death: a closed cohort study. Gastrointest Endosc 2012; 76: 110-117 DOI: 10.1016/j.gie.2012.02.040. (PMID: 22498179)
- 6 Brenner H. et al. Long-lasting reduction of risk of colorectal cancer following screening endoscopy. Br J Cancer 2001; 85: 972-976 DOI: 10.1054/bjoc.2001.2023. (PMID: 11592768)
- 7 Pan J. et al. Colonoscopy Reduces Colorectal Cancer Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis. Am J Gastroenterol 2016; 111: 355-365 DOI: 10.1038/ajg.2015.418. (PMID: 26753884)
- 8 Lin JS. et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 315: 2576-2594 DOI: 10.1001/jama.2021.4417. (PMID: 34003220)
- 9 Rutter MD. et al. Principles for Evaluation of Surveillance After Removal of Colorectal Polyps: Recommendations From the World Endoscopy Organization. Gastroenterology 2020; 158: 1529-1533 DOI: 10.1053/j.gastro.2019.12.052. (PMID: 32240700)
- 10 Cross AJ. et al. Long-term colorectal cancer incidence after adenoma removal and the effects of surveillance on incidence: a multicentre, retrospective, cohort study. Gut 2020; 69: 1645-1658 DOI: 10.1136/gutjnl-2019-320036. (PMID: 31953252)
- 11 Rabeneck L. Surveillance Colonoscopy: Time to Dial it Back?. Gastroenterology 2020; 158: 816-817 DOI: 10.1053/j.gastro.2020.01.010. (PMID: 31930987)
- 12 Helsingen LM. et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. BMJ 2019; 367: l5515 DOI: 10.1136/bmj.l5515. (PMID: 31578196)
- 13 Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011; 33: 88-100 DOI: 10.1093/epirev/mxr004. (PMID: 21633092)
- 14 Puylaert C. et al. Adherence to surveillance guidelines for colorectal adenomatous polyps in the elderly. Neth J Med 2018; 76: 358-364 (PMID: 30362945)
- 15 Mulder SA. et al. A nationwide survey evaluating adherence to guidelines for follow-up after polypectomy or treatment for colorectal cancer. J Clin Gastroenterol 2008; 42: 487-492 DOI: 10.1097/MCG.0b013e31809e703c. (PMID: 18344890)
- 16 Grobbee EJ. et al. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening. Clin Gastroenterol Hepatol 2020; 18: 667-675 DOI: 10.1016/j.cgh.2019.08.015. (PMID: 31419575)
- 17 Meenan RT. et al. A cost-effectiveness analysis of a colorectal cancer screening program in safety net clinics. Prev Med 2019; 120: 119-125 DOI: 10.1016/j.ypmed.2019.01.014. (PMID: 30685318)
- 18 Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of Colonoscopy in screening for colorectal cancer. Ann Intern Med 2000; 133: 573-584 DOI: 10.7326/0003-4819-133-8-200010170-00007. (PMID: 11033584)
- 19 Cenin DR. et al. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. Cancer Epidemiol Biomarkers Prev 2020; 29: 10-21 DOI: 10.1158/1055-9965.EPI-18-1123. (PMID: 31748260)
- 20 Marbet UA. et al. Colonoscopy is the preferred colorectal cancer screening method in a population-based program. Endoscopy 2008; 40: 650-655 DOI: 10.1055/s-2008-1077350. (PMID: 18609465)
- 21 Bundesamt für Statistik (BFS). Wanderungssaldo. 2019 https://www.atlas.bfs.admin.ch/maps/13/de/15607_3027_93_70/24427.html
- 22 FAGAS. Nachsorge nach Resektion von kolorektalen Polypen und von kolorektalen Karzinomen. Schweizerische Ärztezeitung 2001; 82 (37) 1967-1970 DOI: 10.4414/saez.2001.08421.
- 23 Criblez D. Die revidierten FAGAS-Empfehlungen zur Nachsorge nach koloskopischer Polypektomie und kurativ operiertem kolorektalem Karzinom. Schweiz Med Forum 2004; 4: 611-617
- 24 Criblez D. Revidierte Konsensus Empfehlung nach koloskopischer Polypektomie und nach kurativ operiertem colorektalem Karzinom. Forum Med Suisse 2007; 7: 994-999
- 25 Gastroenterologie, S.G.f. Konsensus-Empfehlung zur Nachsorge kolorektaler Polypen nach endoskopischer Abtragung. Zugriff am 02. Oktober 2014 unter: https://sggssg.ch/fileadmin/user_upload/Polypen_SGG_September_2014_DE_neu.pdf
- 26 Whitlock G. et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096 DOI: 10.1016/S0140-6736(09)60318-4. (PMID: 19299006)
- 27 Wieszczy P. et al. Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies. Gastroenterology 2020; 158: 875-883 DOI: 10.1053/j.gastro.2019.09.011. (PMID: 31563625)
- 28 Saini SD, Kim HM, Schoenfeld P. Incidence of advanced adenomas at surveillance colonoscopy in patients with a personal history of colon adenomas: a meta-analysis and systematic review. Gastrointest Endosc 2006; 64: 614-626 DOI: 10.1016/j.gie.2006.06.057. (PMID: 16996358)
- 29 Hassan C. et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2020. Endoscopy 2020; 52: 687-700 DOI: 10.1055/a-1185-3109. (PMID: 32572858)
- 30 BAG. B.f.G.. Tarifstruktur für ärztliche Leistungen. Zugriff am 08. Mai 2018 unter: https://www.bag.admin.ch/bag/de/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/Aerztliche-Leistungen-in-der-Krankenversicherung/Tarifsystem-Tarmed.html
- 31 Nishihara R. et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 2013; 369: 1095-1105 DOI: 10.1056/NEJMoa1301969. (PMID: 24047059)
- 32 Lee JK. et al. Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings. JAMA Intern Med 2019; 179: 153-160 DOI: 10.1001/jamainternmed.2018.5565. (PMID: 30556824)
- 33 Delco F. et al. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland. Aliment Pharmacol Ther 2005; 21: 615-622 DOI: 10.1111/j.1365-2036.2005.02362.x. (PMID: 15740546)
- 34 Djinbachian R. et al. Adherence to post-polypectomy surveillance guidelines: a systematic review and meta-analysis. Endoscopy 2019; 51: 673-683 DOI: 10.1055/a-0865-2082. (PMID: 30909308)
- 35 Levin TR. et al. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology 2018; 155: 1383-1391 DOI: 10.1053/j.gastro.2018.07.017. (PMID: 30031768)
- 36 Kaminski MF. et al. Optimizing the Quality of Colorectal Cancer Screening Worldwide. Gastroenterology 2020; 158: 404-417 DOI: 10.1053/j.gastro.2019.11.026. (PMID: 31759062)
- 37 Lieberman D. et al. Baseline Colonoscopy Findings Associated With 10-Year Outcomes in a Screening Cohort Undergoing Colonoscopy Surveillance. Gastroenterology 2020; 158: 862-874
- 38 He X. et al. Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps. Gastroenterology 2020; 158: 852-861 DOI: 10.1053/j.gastro.2019.06.039. (PMID: 31302144)
- 39 Gupta S. et al. Recommendations for Follow-Up After Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2020; 158: 1131-1153 DOI: 10.1016/j.gie.2020.01.014. (PMID: 32044106)
- 40 de Jonge V. et al. Systematic literature review and pooled analyses of risk factors for finding adenomas at surveillance colonoscopy. Endoscopy 2011; 43: 560-572 DOI: 10.1055/s-0030-1256306. (PMID: 21437854)
- 41 Dorta G. Nachsorge nach koloskopischer Polypektomie und entferntem Kolorektalkarzinom. Swiss Medical Forum 2016; 16 (07) 164-167 DOI: 10.4414/smf.2016.02496.
- 42 Jover R. et al. Rationale and design of the European Polyp Surveillance (EPoS) trials. Endoscopy 2016; 48: 571-578 DOI: 10.1055/s-0042-104116. (PMID: 27042931)
- 43 Chukmaitov A. et al. Association of polypectomy techniques, endoscopist volume, and facility type with colonoscopy complications. Gastrointest Endosc 2013; 77: 436-446 DOI: 10.1016/j.gie.2012.11.012. (PMID: 23290773)
- 44 Reumkens A. et al. Post-Colonoscopy Complications: A Systematic Review, Time Trends, and Meta-Analysis of Population-Based Studies. Am J Gastroenterol 2016; 111: 1092-1101 DOI: 10.1038/ajg.2016.234. (PMID: 27296945)
- 45 Doubeni CA. et al. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology 2019; 156: 63-74 DOI: 10.1053/j.gastro.2018.09.040. (PMID: 30268788)
- 46 Atkin W. et al. Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study. Lancet Oncol 2017; 18: 823-834 DOI: 10.1016/S1470-2045(17)30187-0. (PMID: 28457708)
- 47 Duvvuri A. et al. Risk of Colorectal Cancer and Cancer Related Mortality After Detection of Low-risk or High-risk Adenomas, Compared With No Adenoma, at Index Colonoscopy: A Systematic Review and Meta-analysis. Gastroenterology 2021; 160: 1986-1996 DOI: 10.1053/j.gastro.2021.01.214. (PMID: 33524401)
- 48 Inadomi JM, Issaka RB, BB Green BB. What Multilevel Interventions Do We Need to Increase the Colorectal Cancer Screening Rate to 80%?. Clin Gastroenterol Hepatol 2021; 19: 633-645
- 49 Inadomi JMK. Adherence to Competing Colorectal Cancer Screening Strategies. American Journal of Gastroenterology 2005; 100: S387-S388 DOI: 10.1038/ajg.2015.367. (PMID: 26526080)
- 50 Quintero E. et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706 DOI: 10.1056/NEJMoa1108895. (PMID: 22356323)
- 51 Toes-Zoutendijk E. et al. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. Clin Gastroenterol Hepatol 2020; 18: 1493-1500 DOI: 10.1016/j.cgh.2019.08.021. (PMID: 31442598)
- 52 Greuter MJE. et al. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Ann Intern Med 2017; 167: 544-554 DOI: 10.7326/M16-2891. (PMID: 28973514)
- 53 Robertson DJ. et al. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2017; 152: 1217-1237.e3 DOI: 10.1053/j.gastro.2016.08.053. (PMID: 27769517)